ONC-005
Oncology
PreclinicalActive
Key Facts
About RapaFusyn Pharmaceuticals
RapaFusyn Pharmaceuticals is a private, preclinical-stage biotech based in San Diego, founded in 2018. The company has developed a proprietary platform to create RapaGlues, a unique modality of non-degrading molecular glues that harness the FKBP12 chaperone to target intractable proteins. With a pipeline of eight disclosed programs across oncology and immunology & inflammation, the company is advancing its lead program towards IND and recently secured a significant $44 million Series A financing to fuel its platform and pipeline development.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |